

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D. C. 20549

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 6, 2016**

**ABBVIE INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other Jurisdiction  
of Incorporation)

**001-35565**  
(Commission File Number)

**32-0375147**  
(IRS Employer  
Identification No.)

---

**1 North Waukegan Road**  
**North Chicago, Illinois 60064-6400**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(847) 932-7900**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

AbbVie Inc. (“AbbVie”) held its Annual Meeting of Stockholders on May 6, 2016. The following is a summary of the matters voted on at that meeting.

- (1) The stockholders elected AbbVie’s Class I Directors with terms expiring in 2019, as follows:

<b>Name</b>	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
William H.L. Burnside	1,096,503,500	27,564,642	252,971,981
Brett J. Hart	1,114,820,916	9,247,226	252,971,981
Edward J. Rapp	1,100,224,431	23,843,711	252,971,981

- (2) The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2016, as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>
1,340,179,406	33,985,696	2,875,021

- (3) The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2016 annual meeting, as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
1,060,483,805	56,453,483	7,130,854	252,971,981

- (4) The stockholders did not approve the management proposal regarding the annual election of directors, as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
1,113,543,016	5,999,908	4,525,218	252,971,981

- (5) The stockholders approved the material terms of performance goals under the AbbVie Performance Incentive Plan, as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
1,089,198,311	28,289,479	6,580,352	252,971,981

- (6) The stockholders did not approve a stockholder proposal regarding a drug disposal report, as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
71,469,196	880,815,791	171,783,155	252,971,981

(7) The stockholders did not approve a stockholder proposal regarding a lobbying report, as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
284,683,921	683,454,925	155,929,296	252,971,981

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ABBVIE INC.**

Date: May 10, 2016

By: /s/ Laura J. Schumacher

Laura J. Schumacher  
Executive Vice President, External Affairs,  
General Counsel, and Corporate Secretary